These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 36737296)

  • 1. Re: IL-15 Superagonist NAI in BCG-Unresponsive Non-muscle-invasive Bladder Cancer.
    Suderman J; St-Laurent MP; Black PC
    Eur Urol; 2023 Jun; 83(6):581. PubMed ID: 36737296
    [No Abstract]   [Full Text] [Related]  

  • 2. An Interleukin-15 Superagonist with BCG - A Major Therapeutic Advancement or Just a Small Step in the Right Direction?
    Pietzak EJ; Herr HW
    NEJM Evid; 2023 Jan; 2(1):EVIDe2200264. PubMed ID: 38320108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bacillus Calmette-Guérin (BCG) unresponsive non-muscle-invasive bladder cancer: are the subgroups equal?
    Tan WS; Grajales V; Bree K; Li R; Nogueras-Gonzalez GM; Navai N; Dinney C; Kamat AM
    BJU Int; 2023 Oct; 132(4):384-386. PubMed ID: 37246493
    [No Abstract]   [Full Text] [Related]  

  • 4. IL-15 Superagonist NAI in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer.
    Chamie K; Chang SS; Kramolowsky E; Gonzalgo ML; Agarwal PK; Bassett JC; Bjurlin M; Cher ML; Clark W; Cowan BE; David R; Goldfischer E; Guru K; Jalkut MW; Kaffenberger SD; Kaminetsky J; Katz AE; Koo AS; Sexton WJ; Tikhonenkov SN; Trabulsi EJ; Trainer AF; Spilman P; Huang M; Bhar P; Taha SA; Sender L; Reddy S; Soon-Shiong P
    NEJM Evid; 2023 Jan; 2(1):EVIDoa2200167. PubMed ID: 38320011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SWOG S1605: Moving Beyond Systemic Immune Checkpoint Inhibitor Monotherapy in Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer.
    Kulkarni GS; Wettstein MS
    Eur Urol; 2023 Dec; 84(6):545-546. PubMed ID: 37802681
    [No Abstract]   [Full Text] [Related]  

  • 6. Novel Therapies for High-Risk Non-Muscle Invasive Bladder Cancer.
    Al Hussein Al Awamlh B; Chang SS
    Curr Oncol Rep; 2023 Feb; 25(2):83-91. PubMed ID: 36571706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ADAPT and Improvise: Overcoming Bacillus Calmette-Guérin Unresponsiveness in Non-muscle-invasive Bladder Cancer.
    Maitre P; Sangar V; Choudhury A
    Eur Urol; 2023 Jun; 83(6):495-496. PubMed ID: 36898871
    [No Abstract]   [Full Text] [Related]  

  • 8. A 23-Gene Prognostic Index Predicts Progression and Bacillus Calmette-Guérin Response in Non-muscle-invasive Bladder Cancer.
    Kim SK; Byun YJ; Park SH; Piao XM; Zheng CM; Moon S; Kim K; Song SJ; Kang HW; Kim WT; Lee OJ; Choi YH; Moon SK; Kim WJ; Choi YD; Kim SY; Yun SJ
    Eur Urol; 2024 Apr; 85(4):400-402. PubMed ID: 38216401
    [No Abstract]   [Full Text] [Related]  

  • 9. Predictive clinico-pathological factors to identify BCG, unresponsive patients, after re-resection for T1 high grade non-muscle invasive bladder cancer.
    Ferro M; Barone B; Crocetto F; Lucarelli G; Busetto GM; Del Giudice F; Maggi M; Crocerossa F; Cantiello F; Damiano R; Borghesi M; Bove PL; Papalia R; Mari A; Luzzago S; Soria F; Marchioni M; La Civita E; Terracciano D; Mistretta FA; Piccinelli M; Marmiroli A; Russo GI; Schips L; Hurle R; Contieri R; Perdonà S; Del Prete P; Mirone V; Tataru OS; Musi G; Montanari E; de Cobelli O; Vartolomei MD
    Urol Oncol; 2022 Nov; 40(11):490.e13-490.e20. PubMed ID: 35676172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Underutilization of intravesical chemotherapy and immunotherapy for high grade non-muscle invasive bladder cancer in California between 2006-2018: Effect of race, age and socioeconomic status on treatment disparities.
    Noel OD; Stewart E; Cress R; Dall'Era MA; Shrestha A
    Urol Oncol; 2023 Oct; 41(10):431.e7-431.e14. PubMed ID: 37295979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Increased Age With Decreased Response to Intravesical Instillation of Bacille Calmette-Guerin in Patients With High-Risk Non-Muscle Invasive Bladder Cancer: Retrospective Multi-Institute Results From the Japanese Urological Oncology Research Group JUOG-UC- 1901-BCG.
    Ram P; Mandal S; Das MK; Nayak P
    Urology; 2023 Mar; 173():229. PubMed ID: 36587796
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment patterns and prognosis in patients with Bacillus Calmette-Guérin-exposed high-risk non-muscle invasive bladder cancer: a real-world data analysis.
    Nishimura N; Miyake M; Iida K; Miyamoto T; Tomida R; Numakura K; Inokuchi J; Yoneyama T; Okajima E; Yajima S; Masuda H; Terada N; Taoka R; Kobayashi T; Kojima T; Matsui Y; Nishiyama N; Kitamura H; Nishiyama H; Fujimoto K
    World J Urol; 2024 Mar; 42(1):185. PubMed ID: 38512511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biology of BCG response in non-muscle invasive bladder cancer - 2021 IBCN Updates Part III.
    Reike MJ; Ingersoll MA; Müller DC; Zuiverloon TCM; Strandgaard T; Kamat AM; Williams SB; Seiler R; Todenhöfer T; Dyrskjøt L; Nawroth R; Goebell P; Schmitz-Dräger B; Sfakianos JP; Meeks J; Horowitz A; Black PC
    Urol Oncol; 2023 May; 41(5):211-218. PubMed ID: 36266219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential Gemcitabine plus Docetaxel Is the Standard Second-line Intravesical Therapy for BCG-unresponsive Non-muscle-invasive bladder cancer: Pro.
    Roumiguié M; Black PC
    Eur Urol Focus; 2022 Jul; 8(4):1117-1120. PubMed ID: 34593355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implementation of new treatments for BCG-unresponsive non-muscle-invasive bladder cancer. Considerations in Latin America.
    Fernández MI
    Actas Urol Esp (Engl Ed); 2024 May; 48(4):257-259. PubMed ID: 38615906
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy of hyperthermic intravesical chemotherapy (HIVEC) in patients with non-muscle invasive bladder cancer after BCG failure.
    Pignot G; Baboudjian M; Lebacle C; Chamouni A; Lechevallier E; Irani J; Tillou X; Waeckel T; Monges A; Doisy L; Walz J; Gravis G; Mourey E; Duperron C; Masson-Lecomte A
    World J Urol; 2023 Nov; 41(11):3195-3203. PubMed ID: 36811732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advancements in the diagnosis and treatment of non-muscle invasive bladder cancer: Evidence update of surgical concept, risk stratification, and BCG-treated disease.
    Miyake M; Nishimura N; Fujii T; Fujimoto K
    Int J Urol; 2023 Nov; 30(11):944-957. PubMed ID: 37522629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy and safety outcomes of lower dose BCG compared to intravesical chemotherapy in non-muscle-invasive bladder cancer: A network meta-analysis.
    Kawada T; Yanagisawa T; Bekku K; Laukhtina E; von Deimling M; Chlosta M; Pradere B; Teoh JY; Babjuk M; Araki M; Shariat SF
    Urol Oncol; 2023 Jun; 41(6):261-273. PubMed ID: 37137745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current Therapy and Emerging Intravesical Agents to Treat Non-Muscle Invasive Bladder Cancer.
    Bree KK; Brooks NA; Kamat AM
    Hematol Oncol Clin North Am; 2021 Jun; 35(3):513-529. PubMed ID: 33958148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Editorial Comment to Recent advancements in the diagnosis and treatment of non-muscle invasive bladder cancer: Evidence update of surgical concept, risk stratification, and BCG-treated disease.
    Goto Y
    Int J Urol; 2023 Nov; 30(11):957-958. PubMed ID: 37608457
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.